Mannan binding lectin as an adjunct to risk assessment for myocardial infarction in individuals with enhanced risk by Saevarsdottir, Saedis et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
 
JEM © The Rockefeller University Press $8.00
Vol. 201, No. 1, January 3, 2005 117–125 www.jem.org/cgi/doi/10.1084/jem.20041431
 
ARTICLE
 
117
 
Mannan binding lectin as an adjunct to risk 
assessment for myocardial infarction 
in individuals with enhanced risk
 
Saedis Saevarsdottir,
 
1 
 
Oskar Orn Oskarsson,
 
1 
 
Thor Aspelund,
 
2 
 
Gudny Eiriksdottir,
 
2
 
 Thora Vikingsdottir,
 
1 
 
Vilmundur Gudnason,
 
2 
 
and Helgi Valdimarsson
 
1
 
1
 
Department of Immunology, Landspitali-University Hospital, 101 Reykjavik, Iceland
 
2
 
The Icelandic Heart Association, Heart Preventive Clinic and Research Institute, 201 Kopavogur, Iceland
 
Inflammation can predispose to myocardial infarction (MI), and mannan binding lectin 
(MBL) promotes phagocytic clearance of inflammatory agents, but the predictive value of 
MBL levels for MI is not known. MBL was analyzed in subgroups of the population-based 
Reykjavik study, a cohort of 19,381 participants recruited from 1967. MBL levels were very 
stable over time (self correlation: 0.86). In a cross-sectional group from the original cohort 
(
 
n
 
 
 
  
 
987), high MBL (
 
 
 
1,000 
 
 
 
g/L) was associated with a greatly lowered odds ratio for MI 
(0.64, P 
 
  
 
0.001). To verify this finding, a nested case control sample (
 
n
 
 
 
  
 
1,309) was 
randomly selected from the cohort. High MBL at recruitment was also associated with 
decreased MI risk in this follow-up group, but to a lesser extent and not significant for the 
whole group, smokers, or hypertensive individuals. However, high MBL was as in the cross-
sectional group, associated with greatly decreased MI risk in diabetic (P 
 
  
 
0.02) or 
hypercholesterolemic individuals (P 
 
  
 
0.004). This also applied to raised erythrocyte 
sedimentation rate (P 
 
  
 
0.007). Diabetic patients with high MBL did not have a higher MI 
risk than nondiabetic individuals. Our findings indicate that high MBL may predict decreased 
likelihood of MI, particularly in diabetics, and are consistent with the possibility that MBL 
may promote clearance of atherogenic agents.
 
Several inflammatory markers have been associ-
ated with coronary heart disease (1–4), and this
was recently demonstrated for erythrocyte sedi-
mentation rate (ESR; reference 3) and for
C-reactive protein in the Reykjavik study (4).
Complement-dependent opsonization can fa-
cilitate noninflammatory clearance of immune
complexes, microorganisms, and apoptotic cells
within the liver and spleen (5–9), and mannan
binding lectin (MBL) is a serum protein that can
activate the complement system and thereby
promote phagocytic clearance of various in-
flammatory agents (10, 11). MBL is an oligo-
meric C-type lectin that recognizes certain sugar
patterns on the surface of many microorganisms
(10, 12) and self-components including apop-
totic cells (8, 13), phospholipids (14), and im-
mune complexes (15, 16). The serum concen-
tration of MBL varies from undetectable up to
10,000 
 
 
 
g/L with a median around 1,000 
 
 
 
g/L
in Caucasians (17, 18). Low levels of MBL
(
 
 
 
1,000 
 
 
 
g/L) are mostly caused by three point
mutations (O alleles) in exon 1 of the MBL gene
(in codons 52, 54, and 57) that disrupt the assem-
bly of the oligomers and also by a promoter
polymorphism that is associated with low MBL
production (LX). MBL level of 1,000 
 
 
 
g/L dis-
criminates fairly well between individuals with
and without these variant MBL genotypes (12,
18–20). MBL levels can, however, vary mark-
edly between individuals carrying the same ge-
notype (18, 19). However, within-person varia-
tion of MBL concentration is fairly small also in
patients with chronic inflammatory diseases (17,
21), but can temporarily increase up to threefold
during acute phase responses (10, 22). It is not
known how much MBL is required for optimal
function in vivo, but low serum levels or variant
MBL genotypes have been associated with
certain infections and inflammatory diseases in-
cluding systemic lupus erythematosus (SLE; ref-
erences 12 and 20–22).
Several studies have analyzed MBL in rela-
tion to atherosclerotic outcomes. Low MBL
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levels have been reported to increase the risk of graft occlu-
sion after bypass surgery (23), and variant MBL genotypes
have been associated with carotid artery plaques (24) and
coronary heart disease as evident by coronary artery surgery
(25, 26), coronary events (27), and myocardial infarction
(MI) in patients with SLE (28). However, there was no cor-
relation between MBL levels and peripheral arterial disease
in another study (29), and recent case control studies did not
find significant association between variant MBL genotypes
and hospitalization due to cardiovascular disorders (30) or
vascular complications in type 1 diabetes (31).
The predictive value of MBL levels for MI has not been
analyzed before. We postulated that high MBL might pre-
dict decreased likelihood of MI either independently or in
the context of risk factors that may give rise to MI through
diverse pathogenic mechanisms. To evaluate these possibili-
ties, we first studied cross-sectional and then follow-up case
control groups from the Reykjavik study (32).
 
RESULTS
 
The study groups were, as shown in Fig. 1, subsamples from
the Reykjavik study, a prospective study initiated in 1967. In
brief, the first, referred to as the cross-sectional group, was a
sample from the original cohort of cases with a history of MI
at the age of 70 yr and controls, 70 yr and older, without ev-
idence of MI. The second, referred to as the follow-up
group, was a randomly selected nested sample of middle-
aged individuals from stages one to five of the Reykjavik
study with an average follow-up time of 27 yr.
 
Baseline associations and long-term stability of MBL
 
Baseline characteristics of the study participants are shown in
Table I. The within-self correlation coefficient for MBL lev-
els was 0.86 (95% confidence interval: 0.80–0.91) among 96
participants who provided paired serum samples at an aver-
age interval of 20 yr (7–29), which is above the long-term
consistency for total serum cholesterol (0.60), ESR (0.67),
Figure 1. The design of the Reykjavik study. The cohort consisted of 
all men born between 1907 and 1934 and all women born between 1908 
and 1935 that lived in the greater Reykjavik area. Approximately 70% par-
ticipated, with 9,323 men and 10,058 women. The follow-up group was 
randomly selected from stages one to five of the study. The cross-sectional 
group was recruited from the original cohort and consisted of cases with a 
history of MI at the age of 70 yr and controls, 70 yr and older, without 
evidence of MI.
 
Table I.
 
Baseline characteristics of study participants
 
Cross-sectional group Follow-up group
MI cases Controls MI cases Controls
 
Number in group 457 530 867 442
Gender (male/female) 356/101 410/120 500/367 221/221
Age at examination (yr) 70 (66–73) 75 (72–78) 56 (51–62) 55 (50–61)
Diabetes mellitus (%)
 
a
 
15.3 10.6 5.2 2.5
Total cholesterol (mmol/L) 5.9 (5.2–6.7) 6.0 (5.3–6.9) 6.8 (6.1–7.6) 6.5 (5.7–7.2)
Total triglyceride (mmol/L) 1.3 (1.0–1.9) 1.1 (0.85–1.5) 1.1 (0.85–1.5) 1.0 (0.76–1.4)
Hypertension (%)
 
b
 
67.6 63.8 67.6 53.6
Current or former smoker (%) 80.5 68.1 76.9 67.9
Body mass index (kg/m
 
2
 
) 26.7 (24.5–30.0) 26.1 (23.6–28.4) 25.6 (23.3–28.3) 25.1 (22.7–27.4)
ESR (mm/h) 7 (3–13) 6 (3–12) 9 (4–17) 8 (3–14)
 
Data are median values (lower and upper quartile) or percentages.
 
a
 
Diabetes mellitus diagnosis was based on a questionnaire, fasting plasma glucose 
 
 
 
7 mmol/L, and a 2-h glucose tolerance test 
 
 
 
11.1 mmol/L..
 
b
 
Hypertension was defined as blood pressure 
 
 
 
140/90 mm Hg or the use of antihypertensive medications. 
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and systolic (0.66) and diastolic (0.53) blood pressure, but
similar to that for body mass index in the Reykjavik study
cohort (4). MBL levels did not correlate with the age of the
participants, diabetes mellitus, total serum cholesterol, sys-
tolic or diastolic blood pressure, body mass index, or ESR.
In the follow-up group, smokers had higher MBL than those
who had never smoked with median levels of 1,265 and
1,046 
 
 
 
g/L, respectively (P 
 
  
 
0.001), and men had higher
MBL than women with median levels of 1,339 and 1,034
 
 
 
g/L, respectively (P 
 
  
 
0.001), but these differences were
not observed in the cross-sectional group.
 
MBL and the risk of MI
 
A cut-off level of 1,000 
 
 
 
g/L was used to assess whether a
relatively high level of MBL is associated with decreased risk
of MI, but most individuals without variant MBL genotypes
have levels above this (18–20). This is approximately the
median MBL concentration in Caucasians (18) including
Figure 2. The cross-sectional group. Modifying effect associated with 
high MBL on the risk of MI in individuals with different risk factors. Adjusted 
odds ratios for individuals with MBL levels  1,000  g/L compared with 
those with MBL  1,000  g/L with 95% confidence intervals. An odds ratio 
of one (the vertical line) is the MI risk associated with each risk factor in-
dependent of MBL levels. The multiple logistic regression model was adjusted 
simultaneously for gender, age, body mass index, diabetes mellitus, hyper-
cholesterolemia, hypertension, smoking, and raised ESR with the exception 
of the analyzed covariate. The definition of risk factors is described in 
Materials and Methods.
Figure 3. Comparison of the risk of MI in individuals with each risk 
factor in the follow-up group (n   1,309) and the whole Reykjavik 
study cohort (n   19,381). Odds ratio estimates from a multiple logistic 
regression model for the follow-up group and hazard ratio estimates from 
a Cox regression for the whole Reykjavik study cohort are shown with 
95% confidence intervals adjusted for the same variables as in Fig. 2. The 
definition of risk factors is described in Materials and Methods. 
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Icelanders (17), and we hereafter refer to MBL levels 
 
 
 
1,000
 
 
 
g/L as high and MBL levels 
 
 
 
1,000 
 
 
 
g/L as low.
In the cross-sectional group of individuals with a history
of MI at the age of 70 and event-free controls above that
age, the odds ratio for MI was 0.64 (95% confidence inter-
val: 0.50–0.82; P 
 
  
 
0.001) among individuals with high
MBL (
 
 
 
1,000 
 
 
 
g/L) compared with individuals with low
MBL (Fig. 2). The group was then stratified according to
conventional risk factors to assess the effect of high MBL in
relation to different risk factors. It should be noted that most
individuals had more than one risk factor and, with the
exception of the analyzed covariate, the multiple logistic
regression model adjusted simultaneously for gender, age,
body mass index, diabetes mellitus, hypercholesterolemia,
hypertension, smoking, and raised ESR. High MBL was as-
sociated with a lowered odds ratio for MI in the context of
all these risk factors. The odds ratio estimate was lowest for
diabetic patients, but only a trend was observed for partici-
pants with raised ESR.
The predictive value of these findings was then evaluated
in the prospectively assembled case control group, referred to
as the follow-up group, which was randomly selected from
the original Reykjavik study. As shown in Fig. 3, the risk
profile in this study group largely reflected the whole Reyk-
javik study cohort (
 
n 
 
  
 
19,381). High MBL was also associ-
ated with a decreased MI risk in this group (Fig. 4), but to a
lesser extent and not significantly in the group as a whole
(Fig. 4). However, high MBL was, as in the cross-sectional
group, associated with greatly decreased risk of MI in patients
with diabetes or hypercholesterolemia with adjusted odds ra-
tios of 0.15 (0.027–0.78) and 0.26 (0.10–0.64), respectively.
This also applied for participants with raised ESR with an ad-
justed odds ratio of 0.27 (0.11–0.70), but in hypertensive in-
dividuals and smokers, high MBL was associated with only
marginally decreased MI risk that was not significant.
To evaluate further the association between MBL and MI
in individuals with a particular risk factor, these subgroups
were categorized by their MBL level and compared with in-
dividuals without that risk factor. The baseline MI risk in in-
dividuals with each risk factor independent of MBL is shown
in Fig. 3 for the follow-up group. High MBL was associated
with decreased risk of MI in all risk groups of both study
groups, but a marked variation was observed in this respect
for the different risk factors. Thus, diabetic patients with high
MBL were not at more risk of MI than nondiabetic individu-
als, and this applied both to the cross-sectional and follow-up
groups (Fig. 5, A and B). In the cross-sectional group, hyper-
tensive individuals and smokers with high MBL were also not
at enhanced risk of MI (Fig. 5 A), and this also applied for in-
dividuals with raised ESR in the follow-up group (Fig. 5 B).
However, hypercholesterolemic individuals with high MBL
had enhanced risk of MI compared with participants with
normal cholesterol levels, but the risk was much lower than
that of hypercholesterolemic individuals with low MBL in
both study groups. Thus, if MBL was high, the risk of MI as-
sociated with certain risk factors was not significantly differ-
ent from that observed for the study groups as a whole.
 
Distribution of MBL levels in MI cases and controls
 
The controls had higher MBL levels than the MI patients in
the cross-sectional group with median levels of 1,195 and
938 
 
 
 
g/L, respectively (P 
 
  
 
0.002), whereas the distribution
of the MBL levels was similar in MI cases and controls in the
follow-up group as a whole (Fig. 6 A). However, when
Figure 4. The follow-up group. Modifying effect associated with high 
MBL on the risk of MI in individuals with different risk factors. Adjusted 
odds ratios for individuals with MBL levels  1,000  g/L compared with 
those with MBL  1,000  g/L with 95% confidence intervals. An odds ratio 
of one (the vertical line) is the MI risk associated with each risk factor in-
dependent of MBL levels. The multiple logistic regression model shown is 
adjusted for the same variables as in Fig. 2. The definition of risk factors is 
described in Materials and Methods. 
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MBL levels were compared between MI cases and controls
with individual risk factors, the difference was, again, most
marked in the diabetic patients (Fig. 6 B). Thus, the diabetic
controls had nearly two times higher median MBL levels
than the diabetic MI cases, and this applied both to the cross-
sectional (P 
 
  
 
0.018) and the follow-up (P 
 
  
 
0.029) groups.
The modifying effect associated with MBL on the risk of
MI was observed in both genders. The findings were unaf-
fected by changes in cutoff values, including analysis of
tertiles. Furthermore, the receiver operating characteristic
(ROC) analysis revealed that the 1,000-
 
 
 
g/L cutoff for
MBL discriminated best between MI cases and controls with
diabetes in the follow-up group (Fig. 7).
 
DISCUSSION
 
Previous studies of MBL genotypes and various atheroscle-
rotic outcomes have not been conclusive (24–27, 30), and
the predictive power of serum MBL levels in relation to MI
has not been analyzed before. Our findings are in accordance
with a recent prospective cohort study, in which variant
MBL genotypes were only marginally associated with in-
creased risk of cardiovascular hospitalization or death in gen-
eral, and this was not significant when retested in two case
control studies (30). However, the findings in both of our
study groups showed a similar trend when MBL was ana-
lyzed in the context of conventional risk factors for MI.
Thus, high MBL was associated with greatly decreased risk
Figure 5. Risk of MI in individuals with different risk factors cate-
gorized into subgroups according to their MBL levels (above or below 
1,000  g/L) and compared with all the individuals without that risk 
factor, independent of their MBL level. (A) The cross-sectional group 
and (B) the follow-up group. Odds ratio estimates from a multiple logistic 
regression model adjusted for the same variables as in Fig. 2. The p-values 
indicate the significance of the difference between the subgroups. The 
definition of risk factors is described in Materials and Methods, and the 
number of participants with each risk factor is shown in Figs. 2 and 4. 
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of MI in patients with diabetes or hypercholesterolemia, and
diabetic patients were not at enhanced risk of MI if they had
MBL above the median population level.
Chronic inflammation is now generally accepted to be a
risk factor for MI and this applies for patients with chronic
inflammatory diseases such as SLE and rheumatoid arthritis
(1). A recent study found a strong association between vari-
ant MBL genotypes and the risk of MI in SLE (28), and it is
interesting in this context that we also observed that high
MBL was associated with reduced MI risk in individuals
with raised ESR in the follow-up group, as ESR levels have
previously been shown to predict future risk of MI in the
Reykjavik study cohort (3). The cutoff for raised ESR was
set at 15 mm/h (2), but the effect was also observed, al-
though not as marked, at lower cutoff levels. C-reactive pro-
tein is another inflammatory marker predictive of coronary
heart disease in the Reykjavik cohort (4), but these measure-
ments were not available in this study.
Two reports have shown an association between variant
MBL genotypes and coronary artery surgery (25, 26), and
the latter also indicated that the risk of new coronary events
in these patients was restricted to individuals with raised an-
tibodies against 
 
Chlamydia pneumoniae
 
 (26). MBL binds this
(33) and various other microorganisms (12), and chronic in-
fections may aggravate the atherosclerotic process, possibly
by promoting inflammatory state (1) and autoimmune pro-
cesses (34).
Although high MBL was associated with a greatly re-
duced odds ratio for MI in the cross-sectional group, this did
not reach significance for the follow-up group as a whole. A
recent report from the Strong Heart study showed that vari-
ant MBL genotypes were associated with about threefold in-
creased risk of coronary heart disease in American Indians
(27). In view of our finding that the strongest association be-
tween high MBL and reduced risk of MI was observed in di-
abetic patients, it is of special interest that two thirds of the
cases and one third of the controls in the Strong Heart study
had diabetes. This might explain the strong association be-
tween variant MBL genotypes and MI risk observed in the
group as a whole, but the participants were not stratified ac-
cording to risk factors in this study. Another cross-sectional
study focusing on the association between MBL and ne-
phropathy in type 1 diabetes showed higher MBL levels in
diabetic patients with macrovascular disease, including ische-
mic heart disease, stroke, and peripheral vascular disease com-
pared with diabetic patients without history or signs of such
complications. However, the frequency of variant MBL ge-
notypes was not significantly different between the groups,
and the difference in MBL concentration between the
groups was primarily driven by individuals without variant
MBL genotypes, suggesting that the higher MBL levels in
the patients with vascular complications may reflect an on-
going acute phase response (31). It should be noted that very
few diabetic patients in our study groups were receiving in-
sulin, and the pathogenic mechanisms of vascular complica-
tions in type 1 and 2 diabetes might be different.
The strength of our study is large groups of both genders
from a population-based cohort, which is typical for West-
Figure 6. Distribution of MBL levels in MI cases and controls of 
both study groups (A) as a whole and (B) in diabetic individuals. The 
boxes show the median values and interquartiles, and the fifth percentiles 
of MBL concentrations are shown by the dots.
Figure 7. ROC analysis of MBL levels for predicting MI in diabetic 
patients of the follow-up group. The dots represent empirical values of 
true/false positive fractions for MBL levels of 200 –2,800 in increments of 
200. The slope of the curve was unity for the 1,000- g/L cutoff, so MBL 
levels  1,000  g/L are more representative of a control than a case and 
vice versa. 
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ern societies in terms of cardiovascular risk. The average fol-
low-up time was 27 yr in the follow-up group, the rates of
participation and follow-up were high (32), and the MBL
levels were found to be very stable when measured in the
same individuals on average 20 yr apart. This means that
adults or middle-aged individuals with a high or low level of
MBL are likely to have very similar MBL levels until the age
of 70 yr at least and after the occurrence of MI. The diabetic
subgroups were, as expected, small compared with the whole
study groups, and this limits further analysis. The reduced
risk associated with MBL was nevertheless strong and nota-
bly, the diabetic patients were not at more risk of MI than
nondiabetic individuals if they had high MBL.
Various arbitrary cutoff levels have previously been used
to define insufficient MBL levels (19, 21), but we argued
that it might be more appropriate to ask whether high MBL
is associated with decreased risk. Several previous studies are
based on MBL genotyping (24–27), but DNA samples were
not available in this study, which was initiated in 1967. The
monoclonal antibody used in this study for measuring MBL
levels (clone 131–01; Statens Serum Institute) preferentially
detects functional oligomers of MBL (19). The 1,000-
 
 
 
g/L
cutoff, which approximates the median level of the Icelandic
population (17), was chosen as it discriminates fairly well be-
tween individuals with and without variant MBL genotypes
(12, 18–20), and levels below this have been reported to be
insufficient for clearing infections (21, 22, 33). Analysis of
continuous MBL values and tertiles gave similar results, and
evaluation of the 1,000-
 
 
 
g/L cutoff for predicting MI in di-
abetic individuals showed this level to discriminate best be-
tween MI cases and controls.
Our data do not exclude the possibility that MBL could be
a surrogate marker for risk of MI. However, the MBL levels
did not correlate with any of the measured variables, and there
was no correlation between MBL concentrations and the risk
factors except that men had higher MBL levels than women
and smokers had higher MBL levels than nonsmokers, but this
only applied to the follow-up group. More frequent respiratory
infections in smokers might explain this as MBL concentration
can increase up to threefold during acute phase responses (22).
Our findings are unlikely to be confounded by this, and it
would, in any case, be more likely to diminish than augment
the observed differences. The difference between genders has
not been reported before and it should be noted that the mod-
ifying effects associated with MBL on MI risk were observed in
both men and women. As the gender difference was only ob-
served in the middle-aged follow-up group and not in the el-
derly cross-sectional group, this difference may perhaps be due
to some hormonal influences on MBL production, as has for
instance been shown for growth hormone (35, 36).
This study was not designed to elucidate causal mecha-
nisms. However, as high MBL levels were associated with
decreased likelihood of MI, particularly in diabetic individu-
als and also in hypercholesterolemia, it is interesting to note
that both hyperglycemia and hyperlipidemia increase the flux
of glucose through the hexosamine biosynthetic pathway,
leading to accumulation of 
 
N
 
-acetylglucosamine (GlcNAc).
This sugar is the principal substrate for O-linked and
N-linked glycosylation of various proteins (37). MBL has
high affinity for GlcNAc (10) and has been shown to bind
glycoproteins with terminal GlcNAc residues (38, 39). Fur-
thermore, GlcNAc and mannose residues, which MBL also
binds strongly, are exposed on the apolipoprotein B-100 com-
ponent of oxidized low density lipoprotein (LDL; references
40–42). Oxidation of LDL promotes the formation of im-
mune complexes, and this has been associated with an in-
creased risk of MI (42–44), especially in diabetic patients (45).
Glycation of the apolipoprotein B-100 of LDL is increased in
diabetic patients and glycated LDL is vulnerable for oxidation
(46). MBL has been shown to bind immune complexes (11,
15, 16), and we have already demonstrated that MBL can
bind oxLDL in vitro (unpublished data), as has been demon-
strated for the membrane-bound lectin-like oxLDL receptor
1, another C-type lectin (47). Thus, the findings are consis-
tent with the possibility that MBL may facilitate noninflam-
matory phagocytic clearance of atherogenic agents by the
liver and spleen and thereby reduce their arterial deposition.
Inflammation and apoptosis probably render atherosclerotic
plaques more vulnerable to rupture that may cause coronary
occlusion (48). MBL has also been shown to decrease the
release of proinflammatory cytokines from monocytes (12),
greatly decrease the risk of a systemic inflammatory response
(20), and mediate noninflammatory clearance of apoptotic
cells (8, 13). Our findings suggest that MBL may predict
lower MI risk in individuals with chronic inflammatory dis-
orders. MBL replacement therapy has already finished a phase
I clinical study (49) and might have a therapeutic potential in
the appropriate clinical settings.
We conclude that a relatively high level of MBL may
predict decreased likelihood of MI, particularly in diabetic
patients. As diabetic patients with high MBL had a similar
risk estimate for MI as nondiabetic individuals, MBL mea-
surement has a potential usefulness as an adjunct to cardiac
risk assessment and might actually aid in the evaluation of
the need for preventive treatment. Our observations are in
accordance with and extend previous findings and are sug-
gestive of a biological relevance of MBL in the pathogenic
process leading to coronary occlusion, perhaps by promoting
clearance of atherogenic agents.
 
MATERIALS AND METHODS
 
Subjects and study design.
 
The study was performed in accordance
with the Helsinki Declaration and was approved by the National Bioethics
Committee and the Data Protection Authority in Iceland. All participants
gave informed consent.
Two separate case control groups, recruited by the Icelandic Heart As-
sociation, were analyzed (Table I). As shown in Fig. 1, these groups were
subsamples from the Reykjavik study, a prospective study initiated in 1967
that has been described in detail (32). In brief, all men born between 1907
and 1934 and all women born between 1908 and 1935 and living in the
greater Reykjavik area, where 52% of the nation lived, were invited and
 
 
 
70% participated, a total of 9,323 men and 10,058 women.
The first, referred to as the cross-sectional group, was a case control
sample from the original Reykjavik study cohort of cases with a history of 
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MI at the age of 70 yr and controls, 70 yr and older, without evidence of
MI. The participants were recruited again between 1991 and 1997 for clin-
ical assessment and sampling of blood. Serum was available for 457 cases and
530 gender-matched controls who had not been diagnosed with MI.
The second, referred to as the follow-up group, was a randomly se-
lected nested sample of middle-aged individuals from stages one to five of
the Reykjavik study that were recruited between 1967 and 1991. Individu-
als with a history of MI at recruitment were excluded. Baseline serum sam-
ples were available from 1,309 individuals, including 867 participants who
had suffered MI during the follow-up time and 442 event-free controls.
The average follow-up time was 27 yr (6–34) in December 2001.
96 individuals ended up in both groups and were used as a basis for
within-self correlation measures of MBL levels.
 
Evaluation and ascertainment of events.
 
The evaluation of both
groups included a structured interview, physical examination, collection of
serum samples, and various laboratory tests. Endpoints were nonfatal MI ac-
cording to the MONICA criteria (50) or death from coronary heart disease,
verified from death certificates, hospital, and necropsy records with 
 
 
 
99%
follow-up yield. Detailed account of the recruitment process and ascertain-
ment of events has been published elsewhere (3, 32). Biochemical and he-
matological measurements were made at recruitment by standard methods
as described previously, and the same methodology was used for both study
groups (32). For this study, risk factors for coronary heart disease were de-
fined as follows. Hypercholesterolemia was defined as total cholesterol 
 
 
 
7
mmol/L or the use of lipid-lowering medications (9% of the cross-sectional
group but not recorded in the follow-up study as their use was very uncom-
mon in Iceland during the study period). The lipid analysis was based on to-
tal cholesterol as measurement of high density lipoprotein was only available
at a late stage of the study. Smoking was recorded as a risk factor in partici-
pants who smoked at study entry or had a history of former smoking. Hy-
pertension was defined as systolic blood pressure 
 
 
 
140 mm Hg, diastolic
blood pressure 
 
 
 
90 mm Hg, or the use of antihypertensive medications
(20% in both the cross-sectional and follow-up groups). The diagnosis of
diabetes mellitus was based on a questionnaire and fasting plasma glucose
 
 
 
7 mmol/L or an oral glucose tolerance test with plasma glucose 
 
 
 
11.1
mmol/L 2 h after a 75-g glucose load, according to the American Diabetes
Association’s criteria. It was not possible to distinguish type 1 and 2 diabe-
tes, but very few of the diabetic individuals were treated with insulin. In ad-
dition to participants recorded with diabetes mellitus at entry to the study,
those who were subsequently diagnosed with diabetes, but 
 
 
 
5 yr before the
occurrence of MI, were included as diabetics in the analysis. Inflammation
was considered present if ESR was 
 
 
 
15 mm/h (2).
 
Measurement of MBL.
 
MBL was measured blindly in serum samples
taken at entry when the risk factors were first recorded. A sandwich ELISA
system was used that has been described in detail (17). The monoclonal anti-
body used in this assay (HYB 131–1; Statens Serum Institute) predominantly
binds to the functional oligomers of MBL (19). In brief, two dilutions of the
test sera (
 
1
 
/
 
7 
 
and 
 
1
 
/
 
63
 
) and three control sera with low, medium, and high
MBL concentration were included in each test run and calibrated according
to a standard. The detection limit of the assay was set at 50 
 
 
 
g/L and the in-
tra- and inter-assay variabilities were 3.7 and 11.7%, respectively. The sera
were kept at 
 
 
 
20
 
 
 
C and had never been thawed. The distribution of the
MBL concentrations was independent of the age of the serum samples.
 
Statistical analysis.
 
Mann-Whitney Rank Sum test was used to compare
continuous variables between groups. The association between events of
MI and each risk factor was estimated as an odds ratios with a 95% confi-
dence interval (OR [95% CI]) from a multiple logistic regression model ad-
justed simultaneously for gender, age, body mass index, diabetes mellitus,
hypercholesterolemia, hypertension, smoking, and raised ESR, with the ex-
ception of the analyzed covariate. The logistic regression model was defined
by using a backward selection method beginning with all two-way interac-
tions. Interactions with p-values 
 
 
 
0.2 stayed in the model. The effect of
high MBL on the risk of MI in groups with enhanced risk was assessed in
two ways: (a) by the change in odds ratio estimates from a baseline risk of
one for each risk group and (b) by comparing the risk of MI in each group,
categorized into those with high and low MBL, to the risk of MI in individ-
uals without that risk factor. Hazard ratio estimates from a Cox regression
adjusted for the variables described above were calculated for the whole
Reykjavik study cohort to assess whether the follow-up group was a reflec-
tive sample of the whole cohort. Within-self correlation of MBL in paired
serum samples was estimated with a repeated measures model with sex and
age as covariates. An ROC analysis was used to evaluate the sensitivity and
specificity of the 1,000-
 
 g/L cutoff for predicting MI in diabetic individu-
als. Statistical analysis was performed using SAS (SAS/STAT Version 9.1;
SAS Institute Inc.). All tests were two-sided and the level of significance
was set at 0.05.
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